|
| |
Santaris Pharma to present at
Rodman & Renshaw 3rd Annual Global Healthcare Conference - May 15th 2006
Copenhagen, 11th May 2006:
Santaris Pharma, the Danish biopharmaceutical company developing RNA Antagonist
drugs for the treatment of cancer and other , announced today that Keith
McCullagh, President and Chief Executive Officer, will be presenting an overview
of the company and progress in its product pipeline at the Rodman & Renshaw 3rd
Annual Global Healthcare Conference on Monday May 15th at 15.20 pm Central
European Time. The conference is being held at Le Meridien Beach Plaza Hotel,
Monte Carlo, Monaco on May 15th and 16th, 2006.
A live webcast of the Santaris presentation may be accessed from the Investor
Relations section of the company’s website,
www.santaris.com/frame.cfm?sprog=2&grp=9&menu=1 , where it will also be
archived and available after the presentation.
About Santaris Pharma:
Santaris Pharma A/S is a clinical-stage biopharmaceutical company, engaged in
researching and developing world leading drug candidates for inactivating the
functions of specific disease associated RNAs. These innovative new drug
products are based on the Company’s proprietary LNA® (Locked Nucleic Acid)
technology for the treatment of cancer, metabolic disorders and other serious
diseases. The Company was created in May 2003 and recently completed a €40
million new investment round from an international syndicate of premier life
science venture investors.
The Company’s drug pipeline is comprised of novel RNA Antagonist drugs based on
its unique LNA® chemistry. LNA® drugs, with their high potency and biostability,
have the potential to transform the field of RNA inhibiting therapeutics, making
specific and effective gene silencing a reality in human medicine. If this
potential is realised, even in part, it may be possible to design new drugs to
treat a wide variety of human diseases by switching off the expression of
harmful genes. Santaris Pharma holds the world wide patent rights to the
exploitation of LNA® in pharmaceuticals and presently has three drugs in
preclinical or clinical development. The lead drug candidate, SPC2996, is
currently undergoing an international, multicentre, phase I/II clinical study in
Chronic Lymphocytic Leukemia (CLL).
Further Information
For further information see www.santaris.com
or contact:
Keith McCullagh, President & CEO
Tel. +45 4517 9819
km@santaris.com
ENDS
| |
|
